Blocking of Striated Muscle Degeneration by Serotonin in C. elegans

Carre-Pierrat, Maïté; Mariol, Marie-Christine; Chambonnier, Lucie; Laugraud, Aurélie; Heskia, Fabienne; Giacomotto, Jean; Ségalat, Laurent

doi:10.1007/s10974-006-9070-9

Cited by 33 publications

(32 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DMD is mostly described by a dynamic loss of solid mass and capacity happening in guys because of transformations in the DYSTROPHIN quality situated on the X chromosome, which usually prompts to loss of motion and demise by the age of 30. DYSTROPHIN is both solid and neuronal, being required for cerebrum design and neurotransmission, to such an extent that DMD patients show neurodegeneration related with engine shortfalls and diminished subjective exhibitions (normal IQ is 85 in DMD young men) [174][175][176][177]. DYSTROPHIN is monitored in C. elegans, however its loss-of-capacity in the worm brings about hypercontractility because of debilitated cholinergic movement and does not influence muscle cells [178,179].…”

Section: Pathwaysmentioning

confidence: 99%

Discovering Capacity in Novel Targets: C. Elegans as a Model Life Form in Toxicological Research

Ac¹,

Costa²,

Tec³

et al. 2017

J Clinic Toxicol

View full text Add to dashboard Cite

The nematode Caenorhabditis elegans has risen as a critical creature show in different fields including neurobiology, formative science, and hereditary qualities. Qualities of this creature demonstrate that have added to its prosperity incorporate its hereditary manipulability, invariant and completely depicted formative program, all around portrayed genome, simplicity of support, short and productive life cycle, and little body estimate. These same elements have prompted to an expanding utilization of C. elegans in toxicology, both for robotic reviews and highthroughput screening approaches. We depict a portion of the exploration that has been completed in the territories of neurotoxicology, hereditary toxicology, and ecological toxicology, and additionally high-throughput tries different things with C. elegans including all inclusive screening for sub-atomic focuses of harmfulness and fast danger evaluation for new chemicals. We contend for an expanded part for C. elegans in supplementing other model frameworks in toxicological research.

show abstract

Section: Pathwaysmentioning

confidence: 99%

Discovering Capacity in Novel Targets: C. Elegans as a Model Life Form in Toxicological Research

Ac¹,

Costa²,

Tec³

et al. 2017

J Clinic Toxicol

View full text Add to dashboard Cite

show abstract

“…Despite large differences in anatomical and biochemical properties between mammals and invertebrates, it has been shown that there are enough similarities and correspondences to use C. elegans as a model host for research of a variety of diseases and medications. Many C. elegans mutant strains can mimic human diseases such Alzheimer's disease, Duchenne muscular dystrophy, diabetes, and cancer [76–80] . A very important factor in utilizing C. elegans in antimicrobial discovery is that there are similarities between microbial pathogenesis in mammals and C. elegans ; therefore, compounds with antimicrobial property detected in C. elegans are highly likely to be compounds which can be used in humans.…”

Section: C Elegans In Drug Discoverymentioning

confidence: 99%

UsingCaenorhabditis elegansfor antimicrobial drug discovery

Desalermos

Muhammed

Glavis-Bloom

et al. 2011

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction The number of microorganism strains with resistance to known antimicrobials is increasing. Therefore, there is a high demand for new, non-toxic and efficient antimicrobial agents. Research with the microscopic nematode Caenorhabditis elegans can address this high demand for the discovery of new antimicrobial compounds. In particular, C. elegans can be used as a model host for in vivo drug discovery through high-throughput screens of chemical libraries. Areas covered This review introduces the use of substitute model hosts and especially C. elegans in the study of microbial pathogenesis. The authors also highlight recently published literature on the role of C. elegans in drug discovery and outline its use as a promising host with unique advantages in the discovery of new antimicrobial drugs. Expert opinion C. elegans can be used, as a model host, to research many diseases, including fungal infections and Alzheimer’s disease. In addition, high-throughput techniques, for screening chemical libraries, can also be facilitated. Nevertheless, C. elegans and mammals have significant differences that both limit the use of the nematode in research and the degree by which results can be interpreted. That being said, the use of C. elegans in drug discovery still holds promise and the field continues to grow, with attempts to improve the methodology already underway.

show abstract

“…This first pilot screen served as a proof-of-principle study suggesting that drugs used to treat patients with dystrophin-associated disease can be highlighted in a C. elegans model. A second slightly larger screen of bioactive molecules highlighted serotonin as an even more potent blocker of dys-1-associated muscle degeneration than prednisone and serotonin also partially rescued motility [54]. Similarly, serotonin re-uptake blockers, which can cause synaptic serotonin buildup, also significantly reduced degeneration, albeit to a lesser extent that serotonin itself.…”

Section: Translational Neurosciencementioning

confidence: 99%

C. elegans models of neuromuscular diseases expedite translational research

Sleigh

Sattelle²

2010

Translational Neuroscience

View full text Add to dashboard Cite

The nematode Caenorhabditis elegans is a genetic model organism and the only animal with a complete nervous system wiring diagram. With only 302 neurons and 95 striated muscle cells, a rich array of mutants with defective locomotion and the facility for individual targeted gene knockdown by RNA interference, it lends itself to the exploration of gene function at nerve muscle junctions. With approximately 60% of human disease genes having a C. elegans homologue, there is growing interest in the deployment of lowcost, high-throughput, drug screens of nematode transgenic and mutant strains mimicking aspects of the pathology of devastating human neuromuscular disorders. Here we explore the contributions already made by C. elegans to our understanding of muscular dystrophies (Duchenne and Becker), spinal muscular atrophy, amyotrophic lateral sclerosis, Friedreich’s ataxia, inclusion body myositis and the prospects for contributions to other neuromuscular disorders. A bottleneck to low-cost, in vivo, large-scale chemical library screening for new candidate therapies has been rapid, automated, behavioural phenotyping. Recent progress in quantifying simple swimming (thrashing) movements is making such screening possible and is expediting the translation of drug candidates towards the clinic.

show abstract

Blocking of Striated Muscle Degeneration by Serotonin in C. elegans

Cited by 33 publications

References 25 publications

Discovering Capacity in Novel Targets: C. Elegans as a Model Life Form in Toxicological Research

Discovering Capacity in Novel Targets: C. Elegans as a Model Life Form in Toxicological Research

UsingCaenorhabditis elegansfor antimicrobial drug discovery

C. elegans models of neuromuscular diseases expedite translational research

Contact Info

Product

Resources

About